Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227797 · ClinicalTrials.gov registry record · Phase 1
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02227797 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 66 participants.
The verdict
NCT02227797, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The primary purpose of this study is to identify the optimal dose of voriconazole, an anti-fungal drug often used in people undergoing stem cell transplant. An optimal dose level is one level that provides a good blood level (concentration) of voriconazole without too much toxicity.
Interventions
- DRUG Voriconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227797
The ClinicalTrials.gov registry entry for NCT02227797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voriconazole is the first listed.
NCT02227797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227797 about?
NCT02227797 is a clinical study titled "MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients". The primary purpose of this study is to identify the optimal dose of voriconazole, an anti-fungal drug often used in people undergoing stem cell transplant. An optimal dose level is one level that provides a good blood level (concentration) of voriconazole without too much toxicity.
What is the current status of trial NCT02227797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-01-19. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT02227797?
The interventions under investigation include: Voriconazole (DRUG).
Who is sponsoring clinical trial NCT02227797?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.